Hematologic Oncology Update cover image

Oncology Today with Dr Neil Love — Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Chronic Lymphocytic Leukemia Edition

Hematologic Oncology Update

00:00

The Benefits of Getting Off of BTK Inhibitors

Once you kind of get beyond two to three years and you haven't had in toxicity, you typically don't have any issues with the drug. So we do see some immune benefits getting off of these agents. The captivate study has shown some of that data where the B cells come back. T cell activation comes back. And so I think there is absolute benefit to kind of some immune reconstitution as well.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app